Related by context. All words. (Click for frequent words.) 77 Biologics License Application BLA 76 NDA submission 73 Biologics License Application 72 Marketing Authorization Application MAA 69 sNDA 67 Marketing Authorization Application 66 Investigational 66 Biologic License Application 64 Complete Response 63 Marketing Authorisation Application 63 sBLA 63 Marketing Authorisation Application MAA 62 Biologic License Application BLA 62 New Drug IND 62 application sNDA 62 Marqibo 62 BLA submission 62 Application BLA 62 supplemental Biologics License Application 61 Premarket Approval PMA 61 FDA Approvable Letter 61 pivotal Phase III 61 Phase III clinical 61 Biological License Application 61 NEBIDO 61 Phase III clinical trials 61 PREOS 60 BLA filing 60 approvable letter 60 NDA Submission 60 FDA approvable letter 60 vilazodone 59 Premarket Approval Application 59 Market Approval PMA 59 FDA Complete Response 59 IND Investigational New 58 CIP TRAMADOL ER 58 SILENOR TM 58 Intermezzo ® NDA 58 IND 58 ZEGERID Capsules 58 OFIRMEV 58 Exocrine Pancreatic Insufficiency 58 NEBIDO R 58 INDs 58 Corlux 58 octreotide implant 58 Cellegesic 58 initiate Phase 58 Frova ® 57 Zelrix 57 Investigational Device Exemption IDE 57 Drug Submission 57 alvimopan 57 Luveniq 57 Zenvia ™ 57 Files Investigational 57 Complete Response Letter 57 ANTEGREN 57 Investigational Device Exemption 57 Dyloject TM 57 FDA Accepts 57 Phase 2b clinical 57 PRX # 57 NUVIGIL 57 Junovan 57 Clinical Trial Application 57 Intermezzo R 57 T Pred 57 PREOS R 57 Phase IIb clinical 57 Panzem R 57 Phase IIa trial 57 MAA submission 57 ZEGERID Chewable Tablets 57 Phase IIb 57 Stavzor 56 Phase Ib 56 pivotal Phase 56 balsalazide tablet 56 lorcaserin NDA 56 Flutiform ™ 56 Exalgo 56 Phase 2b 56 oral ridaforolimus 56 Pivotal Phase III 56 Acetavance 56 Amoxicillin PULSYS 56 Icatibant 56 methylnaltrexone bromide 56 Phase 2b study 56 Orathecin 56 Fast Track designation 56 APF# NDA 56 Phase III 56 IND submission 56 Phase 2b trial 56 Zolpimist 56 Approvable letter 56 alogliptin 56 Phase IIa 56 pseudobulbar affect PBA 56 Drug Application 56 Application MAA 56 Daytrana ® 56 markets HP Acthar 56 Levoleucovorin 56 Sanctura XR 56 initiate Phase IIb 56 SILENOR 55 Complete Response letter 55 k premarket 55 dextromethorphan quinidine 55 supplemental biologics 55 proprietary transdermal patch 55 LUCASSIN 55 HP Acthar Gel repository 55 investigational 55 NDA resubmission 55 BLOOM DM 55 Horizant 55 Approvable Letter 55 indiplon capsules 55 Civacir 55 Phase III pivotal 55 Orphan Drug Designation 55 BYDUREON 55 registrational 55 Oracea TM 55 JZP 6 55 fluvoxamine maleate 55 Pennsaid 55 teduglutide 55 Zensana 55 investigational compound 55 BENLYSTA 55 Emezine 55 ruxolitinib 55 resubmission 55 Voraxaze 55 corticotropin injection 55 FOLOTYN ® 55 Prestara TM 55 QNEXA 55 Preotact 55 satraplatin 55 diarrhea predominant irritable 55 confirmatory Phase III 55 Nebido 55 ANDA containing 55 ATryn R 55 Phase 1b trial 55 Ceplene 55 Phase IIa clinical 55 Iluvien 55 Vilazodone 55 Efficacy Results 55 PMA submission 55 PDUFA date 55 subcutaneous RELISTOR 54 Fodosine 54 XiDay 54 peginesatide 54 Omigard 54 severe hypercholesterolemia 54 VIVITROL ® 54 tiapamil 54 Exelbine 54 Oral Suspension 54 Trizytek 54 Rescula 54 TREANDA 54 Phase IIb trial 54 Phase 2a clinical 54 REPLAGAL 54 LymphoStat B TM 54 generation purine nucleoside 54 Preos 54 PIX# trial 54 FIRAZYR 54 iloperidone 54 taliglucerase alfa 54 oxymorphone ER 54 velaglucerase alfa 54 StaphVAX R 54 Silenor ® doxepin 54 Biologics Licensing 54 Renvela 54 Intermezzo ® 54 sNDA submission 54 Drug Administration FDA 54 MONOVISC 54 Pirfenidone 54 diabetic neuropathic pain 54 IND enabling 54 mifamurtide 54 APF# 54 Zenvia TM 54 FACTIVE R gemifloxacin 54 European Medicines Evaluation 54 Augment Bone Graft 54 Neurodex 54 ENTEREG ® 54 Acetavance TM 54 TAXUS Element Stent System 54 XIAFLEX ™ 54 Zingo TM 54 NGX# 54 Glybera R 54 sNDA filing 54 Phenoptin 54 JOULFERON 53 post operative ileus 53 apaziquone 53 ANDAs 53 Xibrom QD 53 prGCD 53 Ereska 53 Fortigel 53 nasal calcitonin product 53 Phase IIa trials 53 granulated mesalamine 53 liver resection surgeries 53 Plicera 53 ILUVIEN ® 53 GATTEX TM 53 Combunox 53 Phase 2a Trial 53 LibiGel ® 53 Rhucin 53 TELINTRA 53 Phase 2a 53 Phase III trials 53 ULTRASE 53 cell lymphoma CTCL 53 dirucotide 53 Ketotransdel ® 53 ONGLYZA ™ 53 PLK1 SNALP 53 OLEPTRO TM 53 Submits Investigational 53 confirmatory Phase 3 53 Bepreve 53 Pennsaid R 53 Flutiform 53 Soliris TM eculizumab 53 Archexin 53 Actemra tocilizumab 53 Omigard TM 53 Topical Interferon Alpha 2b 53 L MTP PE 53 bicifadine 53 Amitiza 53 OROS R Hydromorphone 53 linaclotide 53 Abbreviated New 53 CORLUX 53 EOquin 53 Strativa 53 paliperidone palmitate 53 indiplon 53 testosterone gel LibiGel 53 NYSE Amex PTN 53 Cimzia TM 53 daily tramadol 53 ONCONASE 53 vinorelbine emulsion 53 investigational drug 53 METOZOLV ODT 53 Marketing Authorization 53 Bronchitol 53 submitted Biologics License 53 Fibrillex TM 53 BEMA TM Fentanyl 53 postoperative ileus POI 53 EvaMist TM 53 ORENCIA ® 53 ANDA 52 DAYTRANA TM 52 lucinactant 52 LIALDA 52 BLA 52 Release Tablets 52 Contrave NDA 52 SYCREST 52 Bazedoxifene 52 Dexilant 52 Jerini 52 Dalbavancin 52 KRYSTEXXA TM pegloticase 52 Extended Release Capsules 52 desvenlafaxine 52 ZEGERID Powder 52 PMA Supplement 52 Somatuline Depot 52 Act PDUFA date 52 Phase 1b 52 LEVADEX TM 52 Abstral 52 PDE4 inhibitor 52 ATPace TM 52 Dyloject 52 lubiprostone 52 sevelamer carbonate 52 Inc. Nasdaq VVUS 52 Firdapse 52 SILENOR ™ 52 POSIDUR TM ELADUR TM 52 oral calcitonin 52 Linjeta TM 52 Silenor ® 52 Sular formulation 52 PhosLo 52 Kuvan 52 Phase IIb trials 52 Nasdaq VRTX 52 TRANSDUR Sufentanil 52 REMOXY R 52 Elagolix 52 HFA MDI 52 Loramyc 52 POSIDUR TM 52 Cladribine Tablets 52 Velac 52 Joulferon 52 Ramelteon 52 MHLW 52 CIP ISOTRETINOIN 52 ZALBIN 52 hoFH 52 VEGF Trap 52 Cutanea Life Sciences 52 ADVEXIN p# therapy 52 diabetic peripheral neuropathic pain 52 Metformin GR 52 Phase IIIb clinical 52 milnacipran 52 AzaSite 52 carcinogenicity study 52 OLpur TM H2H 52 Firazyr 52 Xenazine ® 52 Phase IIb Clinical Trial 52 ISO Vorin TM 52 Indiplon 52 ALVESCO R 52 Ketotransdel 52 Dacogen injection 52 ecallantide 52 miconazole Lauriad ® 52 granted Ortec 52 sapropterin dihydrochloride 52 Oracea 52 Drug Application ANDA 52 severe gastroparesis 52 Announces Tentative Approval 52 clofarabine 52 Tramadol ER 52 Divalproex Sodium 52 CDP# 52 Kuvan R 52 THALOMID 52 Anturol ® 52 BEMA Buprenorphine 52 albinterferon alfa 2b 52 ELADUR 52 SNT MC# 52 allosteric modulator PAM 52 Velaglucerase Alfa 52 refractory chronic lymphocytic 52 Zalbin 52 mometasone furoate 52 MBP# [001] 52 JAK inhibitor 52 post herpetic neuralgia PHN 52 fidaxomicin 52 AMITIZA R 52 Xyrem ® 52 MK #B 52 Inc. NASDAQ HITK 52 ALN PCS 52 Orphan Drug designations 52 Cimzia ® 52 BRILINTA 52 Ofirmev 52 Oral Suspension #mg 52 Phase III Clinical Trial 52 Luvox CR 52 Tezampanel 52 novel bactericidal 52 Junovan TM 52 Anturol TM 52 Phase IIb Trial 52 intravenous acetaminophen 52 ezogabine 52 Clevudine 52 solifenacin succinate 52 PNP inhibitor 52 Satraplatin 51 FDA Approval 51 RANK Ligand inhibitor 51 VALSTAR 51 Trexima 51 LUVOX CR 51 CIMZIA r 51 Onsolis 51 Phase III Clinical Trials 51 Mutual Recognition Procedure 51 Roflumilast 51 Fast Track Status 51 Dacogen 51 Solzira TM 51 Itopride 51 Mylan Receives Approval 51 Personalized Immunotherapy 51 Submits NDA 51 Drug Eluting Stent System 51 Surgical Adhesive 51 eprodisate KIACTA TM 51 pralatrexate injection folate analogue 51 orally administered 51 Phase 1b clinical 51 Amigal 51 Phase Ib study 51 ITAX 51 Fortical R 51 Augment Injectable 51 Krystexxa 51 sNDAs 51 ADVEXIN 51 Telavancin 51 Ketotransdel TM 51 European Medicines Agency 51 Evoltra R 51 Vitaros 51 Soliris eculizumab 51 RSD# 51 KRYSTEXXA TM 51 License Application sBLA 51 IIa trial 51 Apricus Bio 51 MethyPatch 51 REMOXY NDA 51 LEVADEX ™ 51 Release Capsules 51 BEMA Fentanyl 51 Frova R 51 Valtropin 51 OMNARIS HFA 51 eprodisate Fibrillex TM 51 BYETTA ® 51 methylnaltrexone 51 GALNS 51 Entereg TM 51 Onco TCS 51 pegloticase 51 Clolar 51 Sycrest 51 Onyx Pharma 51 phase IIa 51 dalbavancin 51 octreotide acetate 51 IV acetaminophen 51 NASDAQ SHPGY 51 Nabi HB Intravenous 51 PDUFA Date 51 Inhalation Aerosol 51 Qutenza 51 orphan designation 51 Flutiform TM 51 Supplemental Biologics License Application 51 TYGACIL 51 ARCOXIA 51 VALSTAR R 51 NUEDEXTA ™ 51 Marketing Approval PMA 51 Femring ® 51 Theratechnologies submitted 51 LUVENIQ 51 phase IIb clinical 51 Evamist TM 51 Cleviprex TM clevidipine 51 Phase IIB 51 Neurodex TM 51 Auxilium Pharma 51 torezolid phosphate 51 Thelin TM 51 Extended Release 51 Orphan Drug designation 51 Pruvel 51 Prolacria 51 KALBITOR ® 51 ACUROX 51 multiple ascending dose 51 Gestiva TM 51 Ferumoxytol 51 Prestara 51 virus HCV protease inhibitor 51 DDP# 51 ofatumumab HuMax CD# 51 Somatuline R Autogel R 51 Fanapt ™ 51 Q#IR 51 gabapentin enacarbil 51 PEG PAL 51 Pegloticase 51 Pivotal Phase 51 ABILIFY R 51 Kristalose ® lactulose 51 zileuton CR 51 acyclovir Lauriad R 51 SUCCEED trial 51 carcinogenicity studies 51 ANDA submission 51 KRYSTEXXA 51 FUSILEV ® 51 Orphan Drug status 51 faropenem 51 BCX# 51 rasagiline tablets 51 intravenous formulation 51 lomitapide 51 Receives Orphan Drug Designation 51 zolpidem tartrate sublingual tablet 51 oral methylnaltrexone 51 Cetrorelix 51 MOZOBIL 51 UPLYSO 51 depressive episodes associated 51 Marketing Authorization Applications 51 Liprotamase 51 subcutaneously administered 51 EpiCept 51 GATTEX 51 GLP toxicology studies 51 Iloperidone 51 commercialize toremifene 51 Fast Track Designation 51 prodrug stimulant 51 Ventavis 51 Kuvan TM sapropterin 51 Vasovist 51 REMOXY ® 51 Asmanex 51 pancreatic insufficiency 51 tezampanel 51 ONCONASE R 51 ThermoDox ® 51 Nerve Targeting Drug 51 Relistor 51 Loramyc R 51 Opana ER 51 PROMUS Element Stent System 50 Clofarabine 50 initiate Phase IIa 50 Onrigin 50 Completes Patient Enrollment 50 Neupro ® 50 Aryplase 50 % uracil topical 50 initiate Phase Ib 50 Testosterone MDTS ® 50 Aerosurf 50 tasimelteon 50 cinacalcet HCl 50 OMAPRO ™ 50 Humanitarian Device Exemption 50 ridaforolimus 50 Zorbtive TM 50 Milnacipran 50 Impax ANDA 50 Phase IIb clinical trials 50 Shionogi 50 ELADUR ™ 50 inhaled liposomal ciprofloxacin 50 submit Biologics License 50 SparVax TM 50 Simulect 50 ATryn ® 50 NASDAQ CXSP announced 50 bazedoxifene 50 Premarket Approval 50 Phase III Trial 50 Zenpep 50 ACOMPLIA R 50 nephropathic cystinosis cystinosis 50 Friedreich Ataxia FRDA 50 Xolegel 50 Alvesco R 50 morphine sulfate extended 50 Zerenex 50 Extended Release Tablets 50 Keppra ® XR 50 Surfaxin LS 50 AzaSite Plus 50 oral hydromorphone 50 NitroMist TM 50 Dextofisopam 50 VYVANSE 50 Saforis 50 SPARLON 50 formoterol fumarate 50 Abstral ® 50 diabetic peripheral neuropathic DPN 50 naproxen esomeprazole magnesium 50 PEG INTRON 50 Investigational Treatment 50 Trobalt 50 Mepact 50 vinflunine 50 Oral Solution 50 Rhucin ® 50 vinorelbine tartrate 50 individualized cellular immunotherapy 50 Silenor NDA 50 Act PDUFA 50 candidate Zentase 50 ketoprofen patch 50 SUMAVEL 50 ibuprofen Injection 50 pharmacokinetic studies 50 Gabapentin GR 50 Celgene Thalomid 50 ® decitabine 50 SinuNase ™ 50 ZEVALIN ® 50 Soriatane 50 chronic idiopathic thrombocytopenic purpura 50 LEVADEX 50 Product Monograph 50 Ixempra 50 subcutaneous formulation 50 SinuNase TM 50 Tolvaptan 50 Nexavar ® 50 non constipation irritable 50 investigational atypical antipsychotic 50 clinical trial 50 Anturol 50 mesylate tablets 50 Antegren 50 Oral Calcitonin 50 Phase II 50 Transcept Pharmaceuticals 50 DPP4 inhibitor 50 BENLYSTA ® 50 miconazole Lauriad R 50 Seroquel XR 50 Meets Primary Endpoint 50 Functional Dyspepsia 50 BioMimetic 50 Neuromodulation System 50 Initiate Phase 50 postherpetic neuralgia PHN 50 RELISTOR ® 50 Evoltra ® 50 XL# anticancer compounds 50 sterile lidocaine patch 50 Risperidone Oral Solution 50 Submits Supplemental 50 SEROQUEL XR 50 CRMD# 50 refractory Hodgkin lymphoma 50 L DOS# 50 Drug Administration FDA Oncologic 50 Ustekinumab 50 Vimovo 50 injectable formulation 50 NitroMist 50 Sanctura 50 lexidronam injection 50 PRISTIQ 50 Probuphine 50 omeprazole sodium bicarbonate 50 Iluvien ® 50 Human Genetic Therapies 50 Evoltra 50 PDX pralatrexate 50 overactive bladder AA# 50 Actonel ® 50 forodesine 50 LibiGel NDA 50 Phase Ia 50 Fentanyl Taifun 50 TachoSil 50 intranasal formulation 50 phase IIb 50 Orapred ODT 50 Ambrisentan 50 ORENCIA R 50 investigational humanized monoclonal antibody 50 Phase IIa clinical trials 50 sublingual tablets 50 acyclovir Lauriad ® 50 GEM #S 50 Daytrana TM 50 Lubiprostone 50 Zyflo 50 Orphan Drug Status 50 MK #A [001] 50 XIAFLEX 50 Entereg R 50 ENZON 50 Ruconest 50 submitted supplemental Biologics 50 STEDESA 50 IL# PE#QQR 50 Empatic TM 50 Pivotal Trial 50 Focalin XR ® 50 Tolevamer 50 highly purified pasteurized 50 Factive 50 pioglitazone HCl 50 topical gel 50 humanized anti 50 Receives Approvable Letter 50 Onrigin TM 50 ONTAK 50 REVLIMID lenalidomide 50 gepirone ER 50 preclinical 50 Viviant 50 Patient Enrollment 50 Fx #A 50 Genasense ® oblimersen 50 formerly LymphoStat B 50 cutaneous T cell 50 Cobalt Pharmaceuticals 50 Zenvia 50 Inc. Nasdaq SEPR 50 ocular hypertension 50 exocrine pancreatic insufficiency 50 Lodotra 50 ONSOLIS 50 Sucampo 50 Hematide ™ peginesatide 50 QRxPharma 50 Drug Submission NDS 50 Testosterone Gel 50 StaphVAX 50 SUPPRELIN R LA 50 Special Protocol Assessment 50 ACUROX ® 50 DASISION 50 Abbott Laboratories Depakote 50 IND Application 50 XOPENEX HFA MDI 50 Inc. OTCBB SYBD 50 aclidinium bromide 50 CHMP 50 Alogliptin 50 Nasdaq DVAX 50 INCB# [002] 50 ELAPRASE 50 IV APAP 50 phase IIb trial 50 CoFactor 50 Plenaxis TM 50 Adcirca 50 reliever tramadol 50 Rapinyl 50 TRANSDUR ® 50 Priority Review 50 Ranexa R 50 AeroLEF 50 oral prodrug 50 AeroLEF TM 50 Nitoman 49 Trelstar R 49 Orazol 49 Rhucin R 49 IPLEX 49 Tesamorelin 49 Inc. NASDAQ AVNR 49 Initiates Phase III 49 topical non steroidal 49 Promacta 49 NOXAFIL 49 Oracea ® 49 diabetic macular edema DME 49 palifosfamide 49 Preotact R 49 novel trazodone formulation 49 brentuximab 49 oral cladribine 49 vapreotide acetate 49 LSE SHP NASDAQ SHPGY 49 Fast Track designations 49 Esbriet pirfenidone 49 faropenem medoxomil 49 Aloxi ® 49 Exalgo TM 49 Genz # 49 Emezine R 49 phase 2a 49 Xcytrin R 49 Phase 2a trial 49 CINTREDEKIN BESUDOTOX 49 Diabetic Macular Edema 49 Sanvar R 49 Cefprozil 49 fostamatinib 49 Orally Disintegrating Tablets 49 Morphine Sulfate 49 CHMP recommendation 49 bifeprunox 49 Pixuvri 49 Sumavel DosePro 49 Avanafil 49 Renvela ® 49 LibiGel 49 Camvia 49 histone deacetylase HDAC inhibitor 49 orphan drug 49 Xyzal R 49 FavId 49 pralatrexate 49 cutaneous T 49 Arzerra ofatumumab 49 ATPace 49 DIFICID ™ 49 Uvidem 49 prokinetic agent 49 Solzira 49 Initiate Clinical Trial 49 Orphan Drug 49 Orphan Therapeutics 49 GRAS notification 49 Horizant ™ 49 BEMA TM LA 49 MNTX 49 XIBROM 49 NVA# 49 Gel repository corticotropin injection 49 hydrochloride tablets 49 levocetirizine 49 phase IIa clinical 49 FOSRENOL 49 LUNESTA TM 49 Acurox 49 proprietary intravenous formulation 49 OMNARIS 49 serotonin norepinephrine reuptake inhibitor 49 Troxatyl 49 hypoparathyroidism 49 By JAMAAL ABDUL 49 PHX# 49 pantoprazole sodium 49 albiglutide 49 RELISTOR 49 Ciclesonide 49 Durezol TM 49 Mometasone Furoate 49 trospium 49 Fanapt TM 49 Resubmission 49 Riquent 49 Dupuytren Contracture 49 NESINA 49 Acurox r Tablets 49 PROVENGE ® 49 NASDAQ BDSI 49 LymphoStat B belimumab 49 Bifeprunox 49 refractory APL 49 Sancuso 49 inhaled formulation 49 Nascobal Nasal Spray 49 AMRIX 49 Stavzor ™ 49 Lung Rx 49 Firazyr ® 49 tramiprosate ALZHEMED TM 49 TSX SHQ 49 HCV protease inhibitor 49 Aloxi Injection 49 Kynapid 49 Granted Orphan Drug 49 Metformin HCl 49 eltrombopag 49 Phase 1a clinical 49 mesylate tablets approved 49 Jevtana 49 R Saizen R 49 Requip XL 49 tetrabenazine 49 QAB# indacaterol 49 Guanilib 49 Amigal TM 49 Submits Biologics License Application 49 dihydrochloride Tablets 49 Raptiva R 49 treat male hypogonadism 49 PrevOnco ™ 49 DU #b 49 EMBEDA 49 Investigational Compound 49 diquafosol tetrasodium 49 DC Bead 49 Xibrom TM 49 Cloretazine R VNP#M 49 AMITIZA ® 49 Phase III Pivotal 49 EMBEDA ™ 49 ABILIFY ® 49 Transdermal System 49 human C1 inhibitor 49 Cinryze TM 49 LEUKINE 49 Febuxostat 49 topical NSAID 49 Serdaxin ® 49 dirucotide MBP# 49 VISICOL R 49 atypical antipsychotic medication 49 NovaDel 49 elotuzumab 49 FUSILEV 49 initiate Phase 1b 49 vernakalant oral 49 TRANSDUR TM Sufentanil 49 Rectogesic 49 Ceflatonin R 49 Alzhemed TM 49 SUTENT ® 49 Proxinium TM 49 Onalta 49 ENRICH trial 49 Octreolin 49 ONSOLIS TM 49 Lenocta TM 49 HZT 49 silodosin 49 Benazepril 49 Zenvia Phase III 49 Gencaro 49 Submits Response 49 Aurexis 49 Kamada AAT 49 autologous cellular immunotherapy 49 GENERIC SILDENAFIL SOFT Generic 49 XIAFLEX ® 49 telavancin NDA 49 Entereg 49 Vernakalant 49 IONSYS TM 49 non nucleoside inhibitor 49 liprotamase 49 norepinephrine reuptake inhibitor 49 Phase 2b Trial 49 dose escalation clinical 49 topically applied SEPA 49 CEQ# 49 Enablex 49 & JPRD 49 ceftobiprole 49 Oporia 49 Palatin Technologies Inc. 49 Panzem R NCD 49 Keppra ® levetiracetam 49 amifampridine phosphate 49 vernakalant hydrochloride 49 ferumoxytol Injection 49 NASDAQ IMCL 49 EGRIFTA TM 49 PhosLo R 49 Inhalation Solution 49 5 lipoxygenase inhibitor 49 approvable letters 49 Enjuvia 49 Indaflex TM 49 Market Authorization Application 49 generation PNP inhibitor 49 Initiates Phase II 49 Ropinirole 49 Drug Applications ANDAs 49 naproxcinod 49 Reloxin ® 49 BROMDAY 49 topical gel formulation 49 Vion Pharmaceuticals 49 BioGlue R 49 Exelbine NDA 49 Study Evaluating 49 Lixisenatide 49 Zavesca r 49 NasdaqGM NTEC today 49 brand eszopiclone 49 tolevamer 49 Raptiva ® 49 registrational trial 49 RECOTHROM R 49 mGluR5 negative 49 Urocidin 49 Celsion Corporation 49 regadenoson 49 tafamidis 49 transdermal patch